vimarsana.com

Latest Breaking News On - Durvalumab imfinzi - Page 1 : vimarsana.com

Durvalumab Plus Guadecitabine Shows PFS Benefit in Cohort of Patients With ccRCC

Durvalumab in combination with guadecitabine was tolerable and led to a PFS benefit in patients with checkpoint inhibitor-naive ccRCC.

Immune Checkpoint Inhibitors for Cancer Treatment

Immune checkpoint inhibitors are promising drugs to treat a variety of cancers and the FDA has approved usage of these checkpoint proteins to treat Cancer.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.